Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andrographolide in progressive multiple sclerosis
NCT02273635Phase 2Unknown
- Sponsor
- InnoBioscience
- Start
- Sep 2014
- Primary completion
- Nov 2016
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of andrographolide in multiple sclerosis (MS), sponsored by InnoBioscience. Primary endpoint: Brain atrophy progression at 24 months. Status: unknown.
02
Drugs
andrographolide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02273635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273635.